Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Ultragenyx Pharmaceuticals won approval for its newest gene therapy on Thursday, helping shares partially reverse a catastrophic dive. The post How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive appeared first on Investor’s Business Daily.
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. The post Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout appeared first on Investor’s Business Daily.
TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart. The post TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry appeared first on Investor’s Business Daily.
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. The post Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares appeared first on Investor’s Business Daily.
Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals. The post Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition? appeared first…
Definium Therapeutics’ synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again. The post Definium, Up 190% This Year, Succeeds Again With Synthetic LSD; Shares Fly appeared first on Investor’s Business Daily.
AstraZeneca stock toppled in late trades Friday after the company’s experimental breast cancer treatment failed to pass muster. The post AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer appeared first on Investor’s Business Daily.
Moderna had too much volatility as a swing trade. But ARK Genomics Revolution ETF allowed us to manage risk better. The post How Cathie Wood’s Fund Gave Us A Back Door To Moderna’s Breakthrough appeared first on Investor’s Business Daily.
Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment. The post Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay appeared first on…
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. The post Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback appeared first on Investor’s Business…
